← All trials
NCT01921426
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2013
- Primary completion
- Jul 1, 2015
- Completion date
- Aug 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Galera TherapeuticsLead sponsor
- University of NebraskaOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of IowaOverall official - principal investigator
- Allegheny Health NetworkOverall official - principal investigator
- Cancer Specialists of South Texas, P.A.Overall official - principal investigator
- Cancer Care NorthwestOverall official - principal investigator
- Wake Forest UniversityOverall official - principal investigator
- Yale UniversityOverall official - principal investigator
- Summa Health SystemOverall official - principal investigator
- Washington University in St. LouisOverall official - principal investigator
- Galera TherapeuticsStudy director
- Lakeland Regional Medical CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.